Population Pharmacokinetics and Individualized Medication of Azithromycin for Injection in Children Under 6 Years Old Publication Population Pharmacokinetics and Individualized Medication of Azithromycin for Injection in Children Under 6 Years Old Explore how weight and age drive azithromycin PK variability; PopPK modelling supports personalized dosing using…CertaraJanuary 20, 2024
Streamlining Your NCA Workflow On-Demand Webinar Streamlining Your NCA Workflow PK analysis intended for submission contends with many data and compliance challenges. To work efficiently,…CertaraJanuary 18, 2024
Population pharmacokinetics of rotigotine extended‑release microspheres for intramuscular injection in early‑stage Parkinson’s disease Publication Population pharmacokinetics of rotigotine extended‑release microspheres for intramuscular injection in early‑stage Parkinson’s disease Discover how body weight meaningfully affects rotigotine ER exposure; race has minimal impact, modelled using…CertaraJanuary 17, 2024
Effect of High-Fat Meal on the Pharmacokinetics and Safety of Valsartan/Amlodipine Fixed Dose Combination Tablets in Healthy Subjects Publication Effect of High-Fat Meal on the Pharmacokinetics and Safety of Valsartan/Amlodipine Fixed Dose Combination Tablets in Healthy Subjects See how high‑fat meals reduce valsartan exposure by over 50% while amlodipine PK is unaffected,…CertaraJanuary 11, 2024
Population pharmacokinetic modeling of ilaprazole in healthy subjects and patients with duodenal ulcer in China Publication Population pharmacokinetic modeling of ilaprazole in healthy subjects and patients with duodenal ulcer in China Learn how the first Chinese PopPK model shows weight, sex, and ulcer status influence ilaprazole…CertaraJanuary 10, 2024
Simultaneous determination of amphotericin B, tobramycin and vancomycin in rabbit ocular biofluids and tissues by LC-MS/MS: An antimicrobial therapy for keratitis and its PK-PD application Publication Simultaneous determination of amphotericin B, tobramycin and vancomycin in rabbit ocular biofluids and tissues by LC-MS/MS: An antimicrobial therapy for keratitis and its PK-PD application Find out how triple‑drug ocular PK‑PD modelling identifies optimal dosing frequency for keratitis therapy using…CertaraDecember 31, 2023
Concurrent determination of anti-microbial and anti-inflammatory drugs in lachrymal fluid and tissue by LC-MS/MS: A potential treatment for microbial keratitis and its PK-PD evaluation Publication Concurrent determination of anti-microbial and anti-inflammatory drugs in lachrymal fluid and tissue by LC-MS/MS: A potential treatment for microbial keratitis and its PK-PD evaluation Explore how validated LC‑MS/MS and PK‑PD simulation support pathogen‑specific dosing for microbial keratitis using Phoenix…CertaraDecember 13, 2023
Bioequivalence Study of Capsules versus Film Tablets Containing Rivaroxaban in Healthy Caucasian Subjects under Fasting and Fed Conditions Publication Bioequivalence Study of Capsules versus Film Tablets Containing Rivaroxaban in Healthy Caucasian Subjects under Fasting and Fed Conditions Discover how capsule and tablet rivaroxaban formulations are bioequivalent with comparable safety, analysed using Phoenix…CertaraNovember 23, 2023
Unveiling the Influence of a High-Fat Meal on the Pharmacokinetics of Oral Globalagliatin, A Glucokinase Activator, in Healthy Chinese Volunteers Publication Unveiling the Influence of a High-Fat Meal on the Pharmacokinetics of Oral Globalagliatin, A Glucokinase Activator, in Healthy Chinese Volunteers See how high‑fat meals increase globalagliatin exposure by 25–35%, supporting food‑related dosing guidance using Phoenix…CertaraNovember 20, 2023
Population pharmacokinetics of rivaroxaban in Chinese deep vein thrombosis patients and the exposure simulation for dosing recommendation. Publication Population pharmacokinetics of rivaroxaban in Chinese deep vein thrombosis patients and the exposure simulation for dosing recommendation. Learn how eGFR strongly influences rivaroxaban clearance; PopPK modelling supports renal‑based dose reductions using Phoenix…CertaraNovember 11, 2023